Aytu BioScience Inc Total Liabilities
Aytu BioScience Inc total liabilities. Based on the latest financial reports, Aytu BioScience Inc (AYTU) has total liabilities worth $76.55 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Aytu BioScience Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aytu BioScience Inc (2007–2025)
Total liabilities of Aytu BioScience Inc from 2007 to 2025. This chart illustrates how Aytu BioScience Inc's total liabilities have evolved over time, based on quarterly financial data.
Aytu BioScience Inc Competitors by Total Liabilities
The table below lists competitors of Aytu BioScience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CU Medical Systems Inc
KQ:115480
|
Korea | ₩39.99 Billion |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
Australia | AU$10.49 Million |
|
VACCITECH (SP.ADR)/1
F:2AB
|
Germany | €25.66 Million |
|
Korean Drug Co. Ltd
KQ:014570
|
Korea | ₩20.08 Billion |
|
Zuleika Gold Ltd
AU:ZAG
|
Australia | AU$2.06 Million |
|
Food and Drinks Public Company Limited
BK:F&D
|
Thailand | ฿519.07 Million |
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩16.86 Billion |
|
Zee Learn Limited
NSE:ZEELEARN
|
India | Rs13.58 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Aytu BioScience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Aytu BioScience Inc balance sheet assets.
Liquidity & Leverage Metrics
Aytu BioScience Inc Total Liabilities Ratios Explained
Aytu BioScience Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aytu BioScience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aytu BioScience Inc (2007–2025)
The table below shows the annual total liabilities of Aytu BioScience Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $105.21 Million | +15.44% |
| 2024-06-30 | $91.14 Million | -7.46% |
| 2023-06-30 | $98.48 Million | +5.54% |
| 2022-06-30 | $93.31 Million | -27.15% |
| 2021-06-30 | $128.10 Million | +121.55% |
| 2020-06-30 | $57.82 Million | +109.24% |
| 2019-06-30 | $27.63 Million | +261.90% |
| 2018-06-30 | $7.64 Million | -30.58% |
| 2017-06-30 | $11.00 Million | -22.86% |
| 2016-06-30 | $14.26 Million | +446.20% |
| 2015-06-30 | $2.61 Million | -60.73% |
| 2014-06-30 | $6.65 Million | +5414.78% |
| 2013-06-30 | $120.53K | +46.33% |
| 2012-06-30 | $82.36K | +40.96% |
| 2011-06-30 | $58.43K | -29.34% |
| 2010-06-30 | $82.70K | +49.18% |
| 2009-06-30 | $55.44K | +15.21% |
| 2008-06-30 | $48.12K | +17.74% |
| 2007-06-30 | $40.87K | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more